Alison Donald

458 total citations
20 papers, 307 citations indexed

About

Alison Donald is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Statistics, Probability and Uncertainty. According to data from OpenAlex, Alison Donald has authored 20 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Physiology and 3 papers in Statistics, Probability and Uncertainty. Recurrent topics in Alison Donald's work include Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (9 papers) and Inhalation and Respiratory Drug Delivery (4 papers). Alison Donald is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (9 papers) and Inhalation and Respiratory Drug Delivery (4 papers). Alison Donald collaborates with scholars based in United Kingdom, United States and Canada. Alison Donald's co-authors include Alison Church, Alex J. Sutton, Thomas M. Siler, John Riley, Glenn Crater, David R. Jones, Edward Kerwin, Ana R. Sousa, François Maltais and Sally Singh and has published in prestigious journals such as The Journal of Physiology, CHEST Journal and Journal of Clinical Epidemiology.

In The Last Decade

Alison Donald

17 papers receiving 306 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison Donald United Kingdom	10	212	181	51	28	20	20	307
Begoña Gómez Spain	3	108 0.5×	28 0.2×	40 0.8×	31 1.1×	19 0.9×	3	197
Sheila McCorkindale United Kingdom	6	104 0.5×	70 0.4×	6 0.1×	32 1.1×	18 0.9×	10	204
Alain DuChêne United States	8	39 0.2×	72 0.4×	25 0.5×	24 0.9×	22 1.1×	11	263
Mike Hallworth United Kingdom	8	19 0.1×	74 0.4×	33 0.6×	12 0.4×	30 1.5×	20	180
Evelyn Flanagan Ireland	7	38 0.2×	31 0.2×	14 0.3×	34 1.2×	7 0.3×	14	166
Ann Abraham United States	9	53 0.3×	30 0.2×	34 0.7×	48 1.7×	26 1.3×	15	309
Nadia Khan Canada	7	30 0.1×	32 0.2×	7 0.1×	6 0.2×	26 1.3×	8	304
Dinesh Pal Mudaranthakam United States	9	28 0.1×	21 0.1×	12 0.2×	46 1.6×	18 0.9×	51	253
Anne Trontell United States	7	76 0.4×	38 0.2×	2 0.0×	16 0.6×	29 1.4×	11	206
Jean Brooks United States	11	1.2k 5.8×	936 5.2×	3 0.1×	20 0.7×	17 0.8×	22	1.3k

Countries citing papers authored by Alison Donald

Since Specialization

Citations

This map shows the geographic impact of Alison Donald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Donald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Donald more than expected).

Fields of papers citing papers by Alison Donald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Donald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Donald. The network helps show where Alison Donald may publish in the future.

Co-authorship network of co-authors of Alison Donald

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Donald. A scholar is included among the top collaborators of Alison Donald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Donald. Alison Donald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donald, Alison, Michael D. Hill, Jean M. Rawling, et al.. (2026). Longitudinal sex differences in cerebrovascular ageing in older adults: results from the brain in motion study. The Journal of Physiology. 604(3). 1088–1112.

Pun, Matiram, A. M. Clarke, Alison Donald, et al.. (2025). Age-related changes in sleep architecture: Effects of body mass index, sex, and mental health in community-dwelling adults using at-home polysomnography. Sleep Medicine. 133. 106629–106629.

Mitrani-Gold, Fanny S, et al.. (2022). Systematic Review and Meta-Analysis to Estimate the Treatment Effect and Inform a Noninferiority Margin for a Phase 3 Noninferiority Trial in Uncomplicated Urogenital Gonorrhea. Sexually Transmitted Diseases. 49(9). 635–643.

Lloyd, Richard, Jackie C. Bloomer, Stephen Charles, et al.. (2020). Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK. Pharmaceutical Research. 37(12). 233–233. 9 indexed citations

Riley, John, Chris Kalberg, Alison Donald, et al.. (2018). Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Research. 4(1). 73–2017. 10 indexed citations

Riley, John, Maggie Tabberer, Nathalie Richard, et al.. (2016). Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials. International Journal of COPD. Volume 11. 1873–1880. 6 indexed citations

Siler, Thomas M., Alison Donald, Dianne M. O’Dell, Alison Church, & William A. Fahy. (2016). A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD. International Journal of COPD. 11. 971–971. 28 indexed citations

Siler, Thomas M., et al.. (2015). Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respiratory Medicine. 109(9). 1155–1163. 61 indexed citations

Siler, Thomas M., et al.. (2014). Efficacy and Safety of Once-Daily Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease: Results of Two Replicate Randomized 12-Week Studies. CHEST Journal. 146(4). 340A–340A. 3 indexed citations

10.

Maltais, François, Sally Singh, Alison Donald, et al.. (2014). Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Therapeutic Advances in Respiratory Disease. 8(6). 169–181. 64 indexed citations

11.

Maltais, François, Sally J Singh, Alison Donald, et al.. (2013). Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: Two randomised clinical trials. European Respiratory Journal. 42(Suppl 57). P761–P761. 6 indexed citations

12.

Riley, John, et al.. (2013). Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD. European Respiratory Journal. 42(Suppl 57). P4145–P4145. 2 indexed citations

13.

Bareille, Philippe, Kelly Hardes, & Alison Donald. (2013). Efficacy and safety of once-daily GW870086 a novel selective glucocorticoid in mild-moderate asthmatics: a randomised, two-way crossover, controlled clinical trial. Journal of Asthma. 50(10). 1077–1082. 11 indexed citations

14.

Crowther, Michael J., Sally R. Hinchliffe, Alison Donald, & Alex J. Sutton. (2013). Simulation-Based Sample-Size Calculation for Designing New Clinical Trials and Diagnostic Test Accuracy Studies to Update an Existing Meta-Analysis. The Stata Journal Promoting communications on statistics and Stata. 13(3). 451–473. 8 indexed citations

15.

Bareille, Philippe, Ann Allen, Kelly Hardes, & Alison Donald. (2013). Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study. Current Drug Therapy. 8(3). 155–163. 2 indexed citations

16.

Cahn, Anthony, et al.. (2013). Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Inhaled Once-Daily Umeclidinium in Healthy Adults Deficient in CYP2D6 Activity: A Double-Blind, Randomized Clinical Trial. Clinical Drug Investigation. 33(9). 653–664. 11 indexed citations

17.

Kelleher, Dennis, Andrew Preece, Rashmi Mehta, et al.. (2011). Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD). European Respiratory Journal. 38(Suppl 55). p834–p834. 4 indexed citations

18.

Mehta, Rashmi, Kelly Hardes, Anthony Cahn, et al.. (2011). Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults. 38. 3972. 12 indexed citations

19.

Sutton, Alex J., et al.. (2010). Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. Journal of Clinical Epidemiology. 63(9). 983–991. 45 indexed citations

20.

Sutton, Alex J., Sarah Donegan, Yemisi Takwoingi, et al.. (2008). An encouraging assessment of methods to inform priorities for updating systematic reviews. Journal of Clinical Epidemiology. 62(3). 241–251. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact